Sun's Caraco plants address FDA issues

Sun Pharmaceutical Industries told Bloomberg that it has addressed the "minor" observations listed in two Form 483s from the FDA following inspections at its Detroit-based Caraco Pharmaceutical Laboratories in January and May. The observations, Bloomberg said, involved temperature-control lapses, some improperly sealed containers and a deviation from quality-control procedures. The Caraco plants were closed and drugs seized in 2009 after problems led to a series of recalls. The FDA allowed the plants to reopen in 2012 after Sun addressed issues. Story | More

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.